key: cord-0996328-ouyr4oke authors: Bhadra, Sanchita; Maranhao, Andre C.; Ellington, Andrew D. title: A one-enzyme RT-qPCR assay for SARS-CoV-2, and procedures for reagent production date: 2020-07-06 journal: bioRxiv DOI: 10.1101/2020.03.29.013342 sha: 879896a0a709ec4eebee356b8c767175356a0c8f doc_id: 996328 cord_uid: ouyr4oke Given the scale of the ongoing COVID-19 pandemic, the need for reliable, scalable testing, and the likelihood of reagent shortages, especially in resource-poor settings, we have developed a RT-qPCR assay that relies on an alternative to conventional viral reverse transcriptases, a thermostable reverse transcriptase / DNA polymerase (RTX)1. Here we show that RTX performs comparably to the other assays sanctioned by the CDC and validated in kit format. We demonstrate two modes of RTX use – (i) dye-based RT-qPCR assays that require only RTX polymerase, and (ii) TaqMan RT-qPCR assays that use a combination of RTX and Taq DNA polymerases (as the RTX exonuclease does not degrade a TaqMan probe). We also provide straightforward recipes for the purification of this alternative reagent. We anticipate that in low resource or point-of-need settings researchers could obtain the available constructs from Addgene or our lab and begin to develop their own assays, within whatever regulatory framework exists for them. We lay out protocols for dye-based and TaqMan probe-based assays, in order to best compare with ‘gold standard’ reagents. These protocols should form the basis of further modifications that can simplify the assay to the use of overexpressing cells themselves as reagents. Developing dye-based and TaqMan probe-based RT-qPCR assays with RTX . CDC TaqMan qRT-PCR primers and probes for SARS-CoV-2 a (adapted from https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html). Description EvaGreen dye-containing RT-qPCR reaction set up shown in Table 2 was used for assembling CDC SARS-CoV-2 N1, N2, and N3 assays. The three assays target three different regions within the nucleocapsid phosphoprotein (N) gene near the 3'-end of the ~30 kb viral genome. In particular, N1 primers (Table 1 ) amplify a 72 nt long region from position 28287 to 28358 of the genome (GenBank Accession No. MN985325.1). The N2 primers produce a 67 bp amplicon from the genomic position 29164 to 29230. Meanwhile, the N3 primers amplify a 72 nt long region from genomic position 28681 to 28752. All reaction mixes were assembled on a cold-block and directly transferred to a real-time PCR machine programmed to cycle through the steps depicted in Table 3 . Melt curve analysis was included after PCR amplification in order to distinguish target amplicons from spurious products. Representative results of SARS-CoV-2 RT-qPCR tests performed using synthetic RNA templates and only RTX or RTX Exo-DNA polymerases are depicted in Figures 1 and 2 . Figure 1 . CDC SARS-CoV-2 N1, N2, and N3 RT-qPCR assays performed using indicated copies of synthetic RNA and RTX DNA polymerase. Panels A, B, and C depict N1, N2, and N3 assays measured in real-time using EvaGreen dye. Amplification curves from reactions containing 100,000 (black traces), 10,000 (blue traces), 1,000 (red traces), and 100 (pink traces) copies of SARS-CoV-2 synthetic N RNA are depicted. Negative control reactions either contained no templates (gray traces) or contained 100,000 copies of synthetic N RNA from MERS-CoV (green traces). Panels D, E, and F depict melting peaks of amplicons determined using the 'Tm calling' analysis in the LightCycler96 software. Average Cq values of all assays are tabulated. Figure 2 . CDC SARS-CoV-2 N1, N2, and N3 RT-qPCR assays performed using indicated copies of synthetic RNA and RTX Exo-DNA polymerase. Panels A, B, and C depict N1, N2, and N3 assays measured in realtime using EvaGreen dye. Amplification curves from reactions containing 100,000 (black traces), 10,000 (blue traces), 1,000 (red traces), and 100 (pink traces) copies of SARS-CoV-2 synthetic N RNA are depicted. Negative control reactions either contained no templates (gray traces) or contained 100,000 copies of synthetic N RNA from MERS-CoV (green traces). Panels D, E, and F depict melting peaks of amplicons determined using the 'Tm calling' analysis in the LightCycler96 software. Average Cq values of all assays are tabulated. These results demonstrate that RTX DNA polymerase alone, with or without proofreading capability, can support dye-based RT-qPCR analyses. In our hands the full-length RTX DNA polymerase was slightly better than the Exo-version, especially in the N3 assay. In order to perform TaqMan RT-qPCR we developed a one-pot two enzyme system comprising RTX and Taq DNA polymerases. TaqMan qRT-PCR reaction set up shown in Table 4 was used for assembling CDC SARS-CoV-2 N1, N2, and N3 assays using either RTX buffer or ThermoPol buffer. Control reactions lacking RTX polymerase were set up using the same recipe except RTX was replaced with water. All reaction mixes were assembled on a cold-block and directly transferred to a real-time PCR machine programmed to cycle through the steps depicted in Table 5 . To compare the RTX-based TaqMan qRT-PCR with qRT-PCR performed using commercial master mix, duplicate reactions ( Table 6 ) were set up using TaqPath™ 1-Step RT-qPCR Master Mix, CG (Thermo Fisher Scientific, Waltham, MA, USA). All reactions were assembled on cold block and then incubated at room temperature (25 °C benchtop) for 2 min prior to being loaded on a realtime PCR machine set to cycle through the steps indicated in Table 7 . The results with either a viral RT (in TaqPath TM commercial mastermix) or RTX are summarized in Table 8 . As can be seen, RTX-based TaqMan assays are of comparable sensitivity and specificity to the gold standard TaqPath assay. While all three RTX-based TaqMan assays performed in ThermoPol buffer consistently yielded Cq values, these were somewhat delayed compared to Cq values obtained with the commercial TaqPath™ Master Mix. In contrast, RTX-based TaqMan assays when executed in RTX buffer yielded Cq values that were closer to Cq values obtained with the commercial mastermix. Perform IMAC column purification in a cold room or allow gravity flow to occur in a refrigerator. Prepare Ni-NTA agarose columns with final column volume (CV) of 1 mL. Apply the clarified lysate from 1 L of expressed culture to a previously equilibrated column and collect the flow-through. Wash column with 20 CV Equilibration Buffer and collect the flow-through. Wash column with 5 CV Wash Buffer and collect flow-through. Elute RTX from column with 5 mL Elution Buffer and transfer to a dialysis cassette with appropriate molecular weight cut-off. Dialyze eluate into 2 L of Ni-NTA Dialysis Buffer for 3-4 hours at 4˚C. Then dialyze eluate into a second 2 L of Ni-NTA Dialysis Buffer overnight at 4˚C. Dialyzed eluate was then passed over an equilibrated 5 mL heparin column (HiTrap™ Heparin HP) and eluted along a sodium chloride gradient (100 mM to 2 M NaCl). The peak corresponding to RTX or its variants could be expected between 40-60% Buffer B. RTX fractions were collected, pooled, and dialyzed into 2 L Heparin Dialysis Buffer for 3-4 hours. Then dialysis cassettes were transferred into 2 L Final Dialysis Buffer overnight where it is expected that the protein sample volume will decrease significantly. Following the final dialysis, protein sample was recovered and protein concentration was determined before storing at -20˚C. A similar protocol should work for Taq and other thermostable polymerases, but may require different dialysis and storage buffers. Summary and opportunities for distribution By obtaining a RTX expression vector and purifying the thermostable reverse transcriptase it should prove possible to carry out RT-qPCR reactions with a sensitivity similar to that already observed for approved kits, with few or no false positive results. The sequence information for plasmids for RTX [pET_RTX-6xHis] and its exonuclease deficient variant, RTX(exo-) [pET_RTX(exo -)-6xHis], bearing a C-terminal 6xHis tags can be found in the Supplemental Information. These plasmids will be uploaded to Addgene in short order, or can be obtained via https://reclone.org/. The Board of Regents of The University of Texas has licensed IP covering RTX to Promega Corporation. Supporting Information Figure S1 . Synthetic evolutionary origin of a proofreading reverse transcriptase Acknowledgements: We acknowledge the extraordinary contributions of the Schoggins lab in making synthetic RNA available on short notice for these assays. /label="bla (AmpR)" rep_origin 1042..1555 /created_by="User" /modified_by="User" /label="M13 ori" rep_origin 1666..2254 /created_by="User" /modified_by="User" /label="pMB1 ori" gene complement(2623..2814) /created_by="User" /label="rop" gene complement(3371..4453) /created_by="User" /label="lacI" promoter 5637..5654 /created_by="User" /label="T7 Promoter" operon 5656..5680 /created_by="User" /label="lacO" misc_feature 5722..5727 /created_by="User" /modified_by="User" /label="NdeI" CDS 5725..8085 /created_by="User" /modified_by="User" /label="RTX" misc_difference 5836..5838 /created_by="User" /label="F38L" misc_difference 6013..6015 /created_by="User" /label="R97M" misc_difference 6076..6078 /created_by="User" /modified_by="User" /label="K118I" misc_difference 6133..6135 /created_by="User" /label="M137L" misc_difference 6865..6867 /created_by="User" /label="R381H" misc_difference 6874..6876 /created_by="User" /label="Y384H" misc_difference 6889..6891 /created_by="User" /label="V389I" misc_difference 7120..7122 /created_by="User" /label="K466R" misc_difference 7201..7203 /created_by="User" /label="Y493L" misc_difference 7264..7266 /created_by="User" /label="T514I" misc_difference 7285..7287 /created_by="User" /label="I521L" misc_difference 7483..7485 /created_by="User" /label="F587L" misc_difference 7714..7716 /created_by="User" /label="E664K" misc_difference 7855..7857 /created_by="User" /label="G711V" misc_difference 7927..7929 /created_by="User" /label="N735K" misc_difference 8026..8028 /created_by="User" /label="W768R" misc_feature 8047..8052 /created_by="User" /label="XhoI" misc_feature 8053..8058 /created_by="User" /label="BamHI" terminator 8104..8226 /created_by="User" /label="T7 Tphi transcription terminator" .1000 /created_by="User" /label="bla (AmpR)" rep_origin 1042..1555 /created_by="User" /modified_by="User" /label="M13 ori" rep_origin 1666..2254 /created_by="User" /modified_by="User" /label="pMB1 ori" gene complement(2623..2814) /created_by="User" /label="rop" gene complement(3371..4453) /created_by="User" /label="lacI" promoter 5637..5654 /created_by="User" /label="T7 Promoter" operon 5656..5680 /created_by="User" /label="lacO" RBS 5708..5714 /created_by="User" /label="RBS" misc_feature 5722..5727 /created_by="User" /modified_by="User" /label="NdeI" CDS 5725..8085 /created_by="User" /modified_by="User" /label="RTX" misc_difference 5836..5838 /created_by="User" /label="F38L" misc_difference 6013..6015 /created_by="User" /label="R97M" misc_difference 6076..6078 /created_by="User" /modified_by="User" /label="K118I" misc_difference 6133..6135 /created_by="User" /label="M137L" misc_difference 6352..6354 /created_by="User" /label="N210D (exo-mutation)" misc_difference 6865..6867 /created_by="User" /label="R381H" misc_difference 6874..6876 /created_by="User" /label="Y384H" misc_difference 6889..6891 /created_by="User" /label="V389I" misc_difference 7120..7122 /created_by="User" /label="K466R" misc_difference 7201..7203 /created_by="User" /label="Y493L" misc_difference 7264..7266 /created_by="User" /label="T514I" misc_difference 7285..7287 /created_by="User" /label="I521L" misc_difference 7483..7485 /created_by="User" /label="F587L" misc_difference 7714..7716 /created_by="User" /label="E664K" misc_difference 7855..7857 /created_by="User" /label="G711V" misc_difference 7927..7929 /created_by="User" /label="N735K" misc_difference 8026..8028 /created_by="User" /label="W768R" misc_feature 8047..8052 /created_by="User" /label="XhoI" misc_feature 8053..8058 /created_by="User" /label="BamHI" terminator 8104..8226 /created_by="User" /label="T7